Apricus Biosciences, Inc. (Nasdaq: APRI), reports that based on a successful and statistically significant reanalysis of its U.S. Phase III ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE